Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Ninenovo; RingConnRingConn Receives FDA 510(k) Clearance for Non-Invasive Blood Oxygen (SpO2) MeasurementShenzhen Ninenovo Technology Limited, the parent company of RingConn, announced that its Smart Ring has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for non-invasive blood oxygen (SpO2) measurement (Clearance No....
- Akeso, Inc.First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon CancerAkeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical study (COMPASSION-40/AK104-313) evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, as monotherapy in...
- AARD 4-DAY DEADLINE ALERT: Aardvark Therapeutics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before October 13, 2026 Lead Plaintiff Deadline - HBSSInvestors who lost money in AARD after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
- MindWave Innovations Signs 3 Client Network Agreements in 10 Days, Extending MindChain into Climate Finance, Sports Media and Insurance; Apimeds Pharmaceuticals US Provides Required NYSE American DisclosureAgreements with AQUAE, Flash Sports & Media and BlockAssure share one model: MindWave builds and operates each network and receives an allocation of 20% of its credits or tokens
- LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that it has granted to Dr. Susan G. Kozauer, the new Chief Medical Officer and Joseph Miller, the new Chief Financial Officer of LB Pharmaceuticals, equity awards outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The equity awards were granted on October 9, 2026, pursuant to the “inducement grant” exception provided under Nasdaq Listing Rule 5635(c)(4) as an inducement material to Dr. Kozauer and Mr. Miller entering into employment with LB Pharmaceuticals.
- CytoMed Therapeutics Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price DeficiencyCytoMed Therapeutics Limited (the “Company”) (NASDAQ: GDTC), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived, cell-based allogeneic immunotherapies, today announced that on October 6, 2026, the Company received a notice from the staff of the Nasdaq Listing Qualifications department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that for the last 30 consecutive business days, the closing bid price of the Company’s ordinary shares (the “Ordinary Shares”) was below the minimum bid price of US$1.00 per share requirement set forth in Nasdaq Listing Rule 5550(a)(2). The Nasdaq notification letter has no current effect on the listing or trading of the Company’s Ordinary Shares on Nasdaq.
- AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today reported the grant of restricted stock units (“RSUs”) covering 150,000 shares of the Company’s common stock to one newly hired non-executive employee of the Company. The award was approved by the Company’s Compensation Committee of the Board of Directors on October 5, 2026 under the Company’s 2025 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of the Company. The RSUs vest in four equal installments, 25% on each annual anniversary of March 9, 2026. The award is subject to the terms and conditions of the Inducement Plan and the terms and conditions of the RSU agreement covering the grant. The RSUs were granted as a material inducement to the employee’s entering into employment with the Company in accordance with Section 711 of NYSE American LLC Company Guide.
- Aetna 2027 Star Ratings Reflect Strong Clinical Quality and Member ExperienceCompanies: CVS HealthAetna 2027 Star Ratings Reflect Strong Clinical Quality and Member Experience Tue, 10/13/2026 - 08:15 Body Originally published on CVS Health Company Newsroom — Aetna®, a CVS Health® company (NYSE: CVS), announced today that more than 69 percent of its Medicare Advantage (MA) members are in 2027 plans rated 4 stars or higher (out of 5 stars) by the Centers for Medicare & Medicaid Services (CMS). These results position Aetna as one of the highest-performing large, publicly traded Medicare Advantage organizations in the Star Ratings program for the third consecutive year and highlight strong performance across various clinical quality, preventive care and member experience measures. "For years, Aetna has been a leader in Star Ratings, and this year's results highlight our distinction in the market," said Steve Nelson, President of Aetna. "We continue to strengthen our business through an unwavering focus on the fundamentals and disciplined execution, and we are encouraged by our performance in areas like clinical quality and operational excellence. This focus gives us confidence in our ability to achieve our goal of returning to appropriate margins while at the same time driving continuous improvement and delivering even better experiences and outcomes for the members who count on us. Outstanding clinical quality performance Our 2027 Star Ratings results demonstrate excellence across several key clinical quality measures. Aetna achieved an outstanding score on Plan All-Cause Readmissions (4.77* out of 5 stars), showcasing the strength of our care coordination programs, provider partnerships and focus on helping members successfully transition between care settings. Keeping members out of the hospital is one of the most important indicators of health care quality. Our high-performing scores on Care for Older Adults Medication Review (5.00*) and Care for Older Adults Functional Status Assessment (4.03*) demonstrate the support we provide members in managing their health and maintaining their independence. Reinforcing our commitment to early detection and preventive care, we earned strong scores on preventive screening measures, including Colorectal Cancer Screening (4.19*) and Breast Cancer Screening (4.07*). Delivering a high-quality member experience Aetna also delivered exceptional results on measures related to member experience and the quality of our customer support. Low rates of Complaints about the Drug Plan (4.29*) demonstrate members' confidence in our service and commitment to resolving issues quickly and effectively. Strong performance on Customer Service (4.04*), Getting Needed Care (3.89*) and Getting Needed Prescription Drugs (4.07*) further highlight our focus on making health care easier to access and navigate. Aetna earned a high score on Rating of Health Care Quality (4.22*), indicating the positive experiences members had with their health care providers and the broader care experience supported by Aetna. In addition, we demonstrated operational excellence through outstanding performance in service and administrative measures, including Call Center Foreign Language Interpreter and Teletypewriter Availability (4.99*), Reviewing Appeals Decisions (4.08*), Plan Makes Timely Decisions About Appeals (4.01*) and Drug Price Accuracy (4.01*). These results underscore our commitment to providing accurate information, fair processes, timely decisions and accessible support for every member. Every year, Medicare evaluates plans based on a 5-star rating system. The Star Ratings are posted at Medicare.gov. Visit AetnaMedicare.com to learn more about the 2027 Aetna Medicare plans. Or call 1-844-588-0041 (TTY: 711), 7 days a week, 8 AM to 8 PM. The Medicare Annual Enrollment Period runs from October 15 through December 7, 2026. A licensed agent may answer your call. NOTE: Information in this release is based on 2027 Star Ratings data published by CMS on October 8, 2026, and MA and MAPD enrollment as of September 2026. Individual plan ratings may vary. *FOR STAR RATING MEASURE SCORES: All scores are based on a rating scale of five stars. About CVS Health CVS Health is a leading health solutions company simplifying health care one person, one family and one community at a time. As of June 30, 2026, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics and a leading pharmacy benefits manager with approximately 87 million plan members. The Company also serves an estimated 37 million people through a broad range of health insurance products and related services. The Company’s integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs. About Aetna Aetna, a CVS Health business, serves an estimated 37 million people with information and resources to help them make better informed decisions about their health care. Aetna offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, and medical management capabilities, Medicaid health care management services, workers' compensation administrative services and health information technology products and services. Aetna's customers include employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups and expatriates. For more information, visit Aetna.com. Aetna Medicare is a HMO, PPO plan with a Medicare contract. Our SNPs also have contracts with State Medicaid programs. Enrollment in our plans depends on contract renewal. See Evidence of Coverage for a complete description of plan benefits, exclusions, limitations and conditions of coverage. Plan features and availability may vary by service area. To send a complaint to Aetna, call the Plan or the number on your member ID card. To send a complaint to Medicare, call 1-800-MEDICARE (TTY users should call 1-877-486-2048), 24 hours a day/7 days a week. If your complaint involves a broker or agent, be sure to include the name of the person when filing your grievance. ©2026 Aetna Inc. Media contact Phil Blando [email protected] Investor contact Larry McGrath 800-201-0938 [email protected] Y0001_9425651a_2027_M Featured Image Type of Content Press Release
- LGF Lab Gas Flow Launches Laboratory Ultra-High Purity Gas Delivery System and Gas Scrubber Systems for Scientific ResearchLGF Lab Gas Flow, a manufacturer of laboratory infrastructure, has released its integrated Ultra-High Purity Gas Delivery Systems and Laboratory Gas Scrubber Systems. Designed for scientific research, biotechnology, and semiconductor fabrication, this equipment provides contamination control, operational safety, and environmental compliance.
- Sling Therapeutics Presents Data from Phase 2b/3 LIDS Clinical Trial Demonstrating Durability of Linsitinib in Thyroid Eye Disease at ASOPRS 57th Annual Fall Scientific SymposiumANN ARBOR, Mich., October 09, 2026--Sling Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the first and only late-stage oral small-molecule therapy for thyroid eye disease (TED), today announced the presentation of efficacy, safety and new durability results from its Phase 2b/3 LIDS trial of linsitinib in adults with moderate to severe active TED. The data were highlighted in an oral presentation and in a poster session at the American Society of Ophthalmic Plastic and
- Vertex Pharmaceuticals IncorporatedVertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis ConferenceBOSTON, October 09, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversib
- PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) CongressBOSTON, October 09, 2026--PureTech Founded Entity Seaport Therapeutics Presents Data from Phase 1 Trial of GlyphAgo at European College of Neuropsychopharmacology Congress